Mohit Bansal
Stock Analyst at Wells Fargo
(4.28)
# 412
Out of 5,128 analysts
187
Total ratings
68.52%
Success rate
9.64%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $3 → $5 | $4.10 | +21.95% | 6 | Jan 5, 2026 | |
| MIST Milestone Pharmaceuticals | Maintains: Overweight | $4 → $8 | $2.22 | +260.36% | 2 | Dec 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,100 → $1,200 | $1,103.51 | +8.74% | 18 | Dec 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $53 → $55 | $56.44 | -2.55% | 10 | Dec 10, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $460 → $515 | $482.63 | +6.71% | 12 | Dec 10, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $700 → $745 | $808.83 | -7.89% | 21 | Dec 10, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $124.03 | +20.94% | 13 | Dec 10, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $155 → $190 | $184.00 | +3.26% | 15 | Dec 10, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $325 | $341.62 | -4.87% | 12 | Dec 10, 2025 | |
| MRK Merck & Co. | Upgrades: Overweight | $90 → $125 | $108.41 | +15.30% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $235 | $170.30 | +37.99% | 3 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $35.12 | +56.61% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $70 | $61.12 | +14.53% | 6 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $232.06 | +12.04% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $36.27 | -3.50% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $100.54 | +49.19% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $42.31 | +11.08% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $65 | $74.52 | -12.78% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $19.08 | +57.23% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $48.62 | +43.97% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.21 | +19.00% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $140.37 | +21.11% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $27.00 | +6,844.44% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $4.82 | +646.89% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $12.05 | +57.68% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.28 | +4,587.50% | 4 | Dec 3, 2019 |
Ironwood Pharmaceuticals
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $4.10
Upside: +21.95%
Milestone Pharmaceuticals
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $2.22
Upside: +260.36%
Eli Lilly and Company
Dec 10, 2025
Maintains: Overweight
Price Target: $1,100 → $1,200
Current: $1,103.51
Upside: +8.74%
Bristol-Myers Squibb Company
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $53 → $55
Current: $56.44
Upside: -2.55%
Vertex Pharmaceuticals
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $482.63
Upside: +6.71%
Regeneron Pharmaceuticals
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $700 → $745
Current: $808.83
Upside: -7.89%
Gilead Sciences
Dec 10, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $124.03
Upside: +20.94%
Biogen
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $155 → $190
Current: $184.00
Upside: +3.26%
Amgen
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $300 → $325
Current: $341.62
Upside: -4.87%
Merck & Co.
Nov 24, 2025
Upgrades: Overweight
Price Target: $90 → $125
Current: $108.41
Upside: +15.30%
Nov 18, 2025
Maintains: Overweight
Price Target: $170 → $235
Current: $170.30
Upside: +37.99%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $35.12
Upside: +56.61%
Oct 28, 2025
Maintains: Overweight
Price Target: $90 → $70
Current: $61.12
Upside: +14.53%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $232.06
Upside: +12.04%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $36.27
Upside: -3.50%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $100.54
Upside: +49.19%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $42.31
Upside: +11.08%
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $74.52
Upside: -12.78%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $19.08
Upside: +57.23%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $48.62
Upside: +43.97%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.21
Upside: +19.00%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $140.37
Upside: +21.11%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $27.00
Upside: +6,844.44%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $4.82
Upside: +646.89%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $12.05
Upside: +57.68%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.28
Upside: +4,587.50%